Articles tagged with Drug Studies
A study published in Science Translational Medicine shows that treating cats with Niemann Pick Type C with cyclodextrin significantly improved their neurological symptoms. The treatment halted disease progression and allowed the cats to live past three years of age, making it a promising potential therapy for human patients.
A recent study published in the American Journal of Public Health found that one in four prison inmates have a diagnosed mental health condition, yet few receive treatment. The study highlights the need for prisons to prioritize validated screening procedures and treatment for mental health disorders.
A new study in JAMA found that patients taking nonsteroidal anti-inflammatory drugs (NSAIDs) along with anticoagulant medications after a heart attack are at higher risk for bleeding and cardiovascular events. The research suggests that there is no safe window for concomitant NSAID use, even short-term treatment.
The JIKI clinical trial found encouraging signs of efficacy for favipiravir in individuals with high or moderate viral replication and less severe visceral lesions. In contrast, patients with very high viral loads and serious visceral involvement showed no efficacy from the treatment. These findings have implications for Ebola virus di...
Researchers at UC San Diego found that LTB4 promotes insulin resistance in obese mice, but blocking the LTB4 receptor improves insulin sensitivity. Genetic deletion or drug inhibition of the receptor prevents and reverses type 2 diabetes in this model.
A new study found that intensive lifestyle intervention or medication can significantly reduce the risk of developing Type 2 diabetes in women who had gestational diabetes. Women with a history of gestational diabetes were less likely to develop diabetes when assigned to take metformin or undergo intensive lifestyle intervention.
A phase three trial found that using sunitinib or sorafenib after surgery did not reduce recurrence in high-risk renal cell carcinoma patients, compared to standard care. The study, E2805, involved 1943 patients and demonstrated no significant differences in disease-free survival or overall survival between treatment groups.
The Alfred P. Sloan Foundation has selected 126 outstanding early-career scientists as recipients of the 2015 Sloan Research Fellowships. These fellowships honor innovative research in eight fields, including chemistry, computer science, economics, and physics.
A new investigational drug, reslizumab, has been shown to reduce asthma attacks in patients who have difficulty controlling the disorder with standard medications. The study found that patients treated with reslizumab were at least 50% less likely to experience severe asthma exacerbations.
Patients with locally advanced kidney cancer did not experience improved outcomes from adjuvant treatment with sorafenib or sunitinib. The average disease recurrence period was similar between those receiving the drugs and those on placebo, suggesting that these treatments may not be beneficial for this patient group.
A University of Iowa expert will testify before the Presidential Task Force on 21st century policing, sharing her research on improving police officer health and wellness. Her pilot intervention program has shown promise in reducing stress-related disability, improving officer retention, and increasing job satisfaction.
USF scientists found that statins produce a significant reduction in cholesterol levels but have failed to substantially improve cardiovascular outcomes. The researchers argue that advocates for statins have used statistical deception to inflate their effectiveness and downplay adverse effects.
The phase II study results indicate that palbociclib can extend disease control and produce tumor shrinkage in ER+ breast cancer patients. Researchers observed significantly longer progression-free survival in hormone receptor-positive patients compared to those with HR-negative breast cancer.
Researchers have identified a new gene, TBK1, associated with sporadic ALS, highlighting the importance of inflammation and autophagy pathways. The study also found that OPTN may be a major player in the disease, interacting physically and functionally with TBK1.
A clinical trial found that all three anti-VEGF drugs were effective in improving vision and preventing vision loss in patients with diabetic macular edema. Aflibercept showed more significant visual gains in patients with worse vision at the start of the trial, providing robust data for clinicians to guide treatment decisions.
A nationwide clinical trial found that Eylea performed better for those with moderate or worse vision loss, while Lucentis and Avastin performed similarly for people with mild DME. The study recruited 660 participants across the US, showing improved visual outcomes for patients treated with Eylea.
Researchers led by Johns Hopkins Medicine discovered that three drugs, Eylea, Avastin, and Lucentis, are effective in treating diabetic macular edema. Eylea performed better than the other two drugs when vision loss was moderate to severe.
Two new NIH-supported trials are examining the safety and acceptability of antiretroviral medicines administered via injection to prevent HIV infection. The studies aim to improve adherence and provide a potential alternative to daily pills for individuals at high risk.
A clinical trial comparing Eylea (aflibercept), Avastin (bevacizumab), and Lucentis (ranibizumab) for diabetic macular edema found that Eylea provided greater visual improvement, especially in patients with moderate vision loss. The study enrolled 660 participants and showed similar results when starting vision was mild.
HIV Prevention Trials Network (HPTN) has initiated two phase 2 studies to evaluate the safety and acceptability of long-acting injectable antiretroviral drugs, a promising advancement in HIV prevention. The studies aim to provide an alternative to daily oral PrEP pills, which have shown limitations in some trials.
A national study found Eylea effective in improving eyesight for individuals with poor vision due to diabetic macular edema. The condition affects an estimated 7.7 million people in the US, and treatment options are limited, making informed decisions crucial.
Fourth and subsequent PET/CT scans improved clinical assessment and management change in lung cancer patients, with 52.28% positive and 47.7% negative results for recurrence or metastasis. The scans resulted in treatment changes in 28.1% of cases, with new treatments initiated in 20.4%.
A study published in PLOS Medicine found that pharmaceutical industry self-regulation in the UK and Sweden had significant violations, with nearly 20% of cases being serious breaches. The researchers analyzed complaints and rulings to find that charges incurred by companies were a small percentage of annual sales revenue.
A study found that varenicline was effective in helping smokers reduce their cigarette consumption and eventually quit. The medication produced greater reductions in smoking prior to quitting and increased smoking cessation rates at the end of treatment.
A phase 3 trial found eliglustat significantly improved spleen volume reduction by 30%, hemoglobin levels, and platelet count in adults with untreated Gaucher disease type 1. The treatment showed no serious adverse events or patient discontinuations.
A study of over 1,500 cigarette smokers found that combining varenicline with cutting back on cigarette consumption increased long-term success in quitting. Smokers who reduced their smoking rate before attempting to quit were four times more likely to succeed at six months and two times more likely to quit at 12 months.
A recent Phase III study has shown that alirocumab significantly lowers LDL-C levels compared to ezetimibe. The treatment's safety profile is comparable to ezetimibe, making it a viable option for patients with primary hypercholesterolemia at moderate CV risk.
A study in Lancet Oncology suggests continued treatment with YONDELIS for advanced soft-tissue sarcoma patients who have not progressed after six courses improves progression-free survival. The results also indicate that a drug holiday may worsen outcomes.
Choosing a screen name with a letter starting in the top half of the alphabet can maximise online dating success. A 70:30 ratio of who you are and what you're looking for is also key, while humour, physical fitness, and genuine profiles can increase likability. Men and women have different preferences when it comes to names and traits.
A U-M study found that switching to generic glaucoma medication led to improved adherence rates among patients. Lower copays after the introduction of generics were a key factor in this improvement. However, black patients with severe disease showed decreased adherence compared to white patients.
In a Phase III study, lenvatinib showed dramatic improvement in progression-free survival for patients with advanced radioiodine-refractory thyroid cancer. The therapy significantly improved overall response rate and survival rates compared to placebo.
A recent study published in the New England Journal of Medicine shows that endovascular treatment can dramatically improve patient outcomes after an acute ischemic stroke, increasing positive outcomes from 30% to 55%. The treatment resulted in a 50% reduction in deaths and restored blood flow to the brain.
The American Stroke Association is honoring three researchers for their groundbreaking work in stroke prevention and treatment. Graeme J. Hankey, Michael Chopp, and Lewis B. Morgenstern are receiving awards for their lifetime contributions to the field of stroke research.
Researchers found that targeting a single protein, VP24, was sufficient to protect monkeys from Ebola virus infection. The medication, AVI-7537, also reduced viral load and liver/kidney damage in infected animals.
A study found that only 4% of published clinical trials mentioned FDA inspection violations, despite 74% having protocol violations. The FDA's lack of transparency and notification to journals contributes to this issue, making it difficult to track research misconduct.
Researchers at the Buck Institute discovered how rapamycin inhibits mTORC2, a complex linked to metabolic side effects. The study suggests that manipulating FK506 binding proteins could selectively target mTORC1, reducing side effects and improving longevity outcomes.
Two major studies strengthen the case for abiraterone as a treatment option for men with advanced prostate cancer. The trials found that receiving abiraterone before chemotherapy significantly extended men's lives by an average of four months, compared to those who did not receive it.
Researchers identified systolic blood pressures above 150 as a critical threshold for increased risk of death or cardiovascular events. Delays in intensifying treatment by over 1.4 months also tied to higher risk, while reassessments beyond 2.7 months increased mortality.
A new NIH study suggests that paramedics may be able to start therapy as soon as stroke is suspected, potentially reducing the impact of brain damage. The study demonstrated the feasibility of early therapy in the ambulance, with 74.3 percent of patients receiving a study intervention within 60 minutes of stroke onset.
Researchers found that retigabine, an approved anti-epilepsy drug, preserved brain tissue in a mouse model of stroke and prevented loss of balance control. Histological analysis showed significantly reduced damage to the tissue after the stroke, up to five days after.
A new method has been developed to deliver promising treatments to stroke patients quickly, thanks to the work of paramedics. By working with paramedics in the field, intravenous medications can be given to patients within the 'golden hour,' the window in which brain damage is minimized.
The VOICE trial found that women who used tenofovir gel had a lower risk of HIV, despite overall product non-adherence being high. Tenofovir gel reduced HIV risk by 14.7% for those who used it, but the study as a whole showed products were not effective in preventing HIV.
Researchers at the University of Helsinki identified an alternative cell pathway promoting blood vessel growth that may explain why certain cancer therapies are failing to improve patient survival. This discovery could help clarify confusing trial results and potentially lead to new treatments for ovarian cancer and other cancers.
A study by Dr. Timothy R. Smith and colleagues found that over three-fourths of US neurosurgeons practice defensive medicine, ordering extra tests and procedures to mitigate malpractice risks. Rates were highest in states with high-risk liability environments, where neurosurgeons reported stopping procedures due to fear of lawsuits.
The DFG is funding four new clinical trials addressing urgent questions in patient-oriented research, including surgery for metastatic stomach cancer and individualised chemotherapy for certain breast cancers. Over 1,160 patients will participate in the trials, which will test efficacy of new procedures over a three-year period.
A new study published in Neurology found that low-frequency deep brain stimulation at 60Hz significantly improves swallowing dysfunction and freezing of gait in Parkinson's patients. This treatment is more effective than standard high-frequency DBS at alleviating these symptoms, which can lead to disability and mortality.
Researchers at Scripps Research Institute have identified drug candidates targeting biological pathways involved in brain cell destruction in Parkinson's disease. The new compounds selectively inhibit JNK kinases, which play a central role in the disease, and show promise as potential therapeutics.
Researchers from Indiana University and Regenstrief Institute call for further research to determine if medications' adverse cognitive effects can be reversed. They also highlight the need for safer alternatives to prevent Alzheimer's disease and other dementing disorders.
A large study links taking commonly used medications with anticholinergic effects to a significantly increased risk of developing dementia and Alzheimer's disease. People taking certain medications at high doses or for longer periods are estimated to be at greater risk for developing dementia.
The CUDC-101 clinical trial, conducted at the University of Colorado Cancer Center, demonstrated activity against key drivers of head and neck cancer. In the study, patients with medium- to high-risk head and neck cancer showed significant results after treatment with CUDC-101 combined with radiation and chemotherapy.
A large study found that younger adults with isolated systolic hypertension have a significantly higher risk of cardiovascular disease and coronary heart disease. Women in this age group are particularly at risk, with a 55% increase in cardiovascular death compared to their male counterparts.
Researchers examined 50 years of sleep research to investigate whether improving sleep early in life can delay or reverse age-related changes in memory and thinking. The findings suggest that sleeping well in middle age predicted better mental functioning 28 years later.
The EORTC PAMM Group discusses the importance of considering individual patient characteristics and tumor genetics in cancer treatment. Pharmacogenetics can help prescribe efficacious treatment and lower toxicity, improving patient outcomes.
Long-acting cabotegravir injections have been shown to be highly protective against vaginal transmission of a virus similar to HIV in two studies involving female monkeys. The drug's potential to improve adherence and offer an additional option for HIV prevention has sparked hope among researchers.
A public health program promoting EPT increased treatment use, reducing chlamydia and gonorrhea rates, while also contributing to a state-wide reduction in both diseases.
A clinical trial examined the safety and effectiveness of lisdexamfetamine in treating moderate to severe binge eating disorder. The study found that higher doses of lisdexamfetamine (50-70mg/day) were effective in decreasing binge-eating days and episodes, with a significant improvement in four-week cessation rates.
A randomized clinical trial compared the safety and effectiveness of combination therapy with rifapentine and isoniazid to treatment only with isoniazid. The study found that combination therapy was as effective in preventing TB in children, with zero cases reported in the combination group compared to three in the isoniazid-only group.
Researchers found that 'normal' metabolizers had better quit rates with varenicline versus the nicotine patch, while slow metabolizers could benefit from the patch. The study suggests tailoring treatment to an individual's nicotine breakdown speed may be a viable strategy to improve quit rates.
A clinical trial conducted by the NIH found that 38 out of 40 volunteers with HCV infections were cured after receiving a combination of three direct-acting oral drugs for six weeks. This short duration therapy may prove relevant for global elimination of hepatitis C, where simple and well-tolerated treatment is required.
A systematic evidence review found that several common treatments for knee osteoarthritis are effective for pain relief, with injectable therapies being the most effective. The review also introduced a new reporting guideline called TRIPOD to improve the quality of reporting in published articles describing prediction model studies.